1. Summary of the notifications

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency notifications from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 18 and 23 September 2019 respectively.

In the first notification, BlackRock, Inc., has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its holding of UCB shares with voting rights has increased and has crossed the 5% threshold on 17 September 2019.

On 17 September 2019, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 790 594 UCB shares with voting rights (versus 9 708 971 in its previous notification), representing 5.03% of the total number of shares issued by the company (194 505 658) (versus 4.99% in its previous notification), as well as 465 583 equivalent financial instruments (versus 451 993 in its previous notification) representing 0.24% of the total number of shares issued by the company (versus 0.23% in its previous notification).

In the second notification, BlackRock, Inc., has notified that, following a disposal of UCB shares with voting rights by its affiliates, its holding of UCB shares with voting rights has decreased and has crossed downwards the 5% threshold on 20 September 2019.

On 20 September 2019, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 702 525 UCB shares with voting rights, representing 4.99% of the total number of shares issued by the company, as well as 460 159 equivalent financial instruments, representing 0.24% of the total number of shares issued by the company.
2. **Further information**

This press release and the detailed transparency notifications are available on UCB SA/NV’s website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following [link](#).

---

**Investor Relations**

Antje Witte,  
Investor Relations, UCB  
T +32 2 559 94 14,  
antje.witte@ucb.com

Isabelle Ghellynck,  
Investor Relations, UCB  
T +32 2 559 95 88,  
isabelle.ghellynck@ucb.com

**About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news